Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (14878)	12/22/2004 4:33:46 PM
From: Arthur Radley	Respond to of 52153

Tuck, Thanks for the links...it appears that several companies have tried to address this insulin issue...with little luck! AMLN sure has been a roller coaster, but if they don't get it right with their current efforts I think they might be doomed. FLML tried to partner their approach, but appears this deal has collapsed. For those suffering this malady, one could hope for a better solution than those daily shots. I have just a small position in NKTR...it appears they will do okay without this insulin project, but it sure would get them to profitability sooner. I just can't see NKTRs delivery system not have the same issues as ARDM.